SCHEMBL7061589

SCHEMBL7061589

CC(C)(C)NS(=O)(=O)c1ccccc1-c1ccc(NC(=O)CCl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
HTT P42858 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MITF O75030 1/20 0.54
GSTO1 P78417 3/20 0.53
FPR2 P25090 2/20 0.48
FPR1 P21462 1/20 0.48
ALOX5AP P20292 7/20 0.48
FEN1 P39748 7/20 0.48
PRMT1 Q99873 1/20 0.47
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
RNF4 P78317 1/20 0.44
GPR119 Q8TDV5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7086229 0.83 KMT2A (0.55) ALDH1A1HTTRAB9ALMNAMAPT
SCHEMBL7364780 0.82 ALOX5AP (0.51) ALDH1A1HTTSMN1; SMN2FPR2FPR1
SCHEMBL6749780 0.82 PTPN1 (0.53) FPR2FPR1ALOX5APFEN1GPR119
Cyclopentane SCHEMBL7093842 0.81 FPR2 (0.52) ALDH1A1FPR2FPR1ALOX5APFEN1
SCHEMBL6807899 0.81 FPR2 (0.50) NPC1RAB9AFPR2FPR1ALOX5AP
SCHEMBL6752209 0.80 ALOX5AP (0.48) FPR2FPR1ALOX5APFEN1GPR119
SCHEMBL890655 0.78 ALOX5AP (0.53) ALOX5APFEN1GPR119
SCHEMBL7190899 0.77 ALOX5AP (0.55) ALOX5APFEN1
SCHEMBL890827 0.76 F10 (0.45) ALDH1A1HTTFPR2FPR1ALOX5AP
SCHEMBL1968159 0.76 ALOX5AP (0.59) ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030166694-A1 Glycinamides MERCK PATENT GMBH (DE) 2003-09-04 US disclosed
US-6043257-A ANTICOAGULANT; PYRIDINE SUBSTITUTED INDAZOLE COMPOUND E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-03-28 US disclosed
EP-0960102-A1 AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN Du Pont Pharmaceuticals Company (US) 1999-12-01 EP disclosed
US-5886191-A ANTICOAGULANTS DUPONT PHARMACEUTICALS COMPANY (US) 1999-03-23 US disclosed
WO-1998001428-A1 AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN DU PONT PHARMACEUTICALS COMPANY (US) 1998-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166694-A1 Glycinamides F11, SERPINC1, F13A1 ALDH1A1 540/4885HTT 4521/4885NPC1 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.